VB Spine entered into a partnership to fund research of molecular genetics affecting pediatric scoliosis. The research will be conducted by Dr. Alain Moreau of the Centre de recherche Azrieli du CHU Sainte-Justine, Montreal, Canada.
In its agreement, VB Spine will receive exclusive worldwide license to commercialize and distribute any predictive scoliosis tests derived from Dr. Moreau’s scoliosis research.
Dr. Moreau’s research began in 2001 with a focus on understanding the biological mechanisms behind idiopathic scoliosis and identifying whether biomarkers present in patient blood could help predict spinal deformity progression. Initial clinical studies launched in 2006 successfully demonstrated proof of concept, and subsequent peer-reviewed research has continued to validate the underlying science. The next phase of the project is expected to focus on further clinical validation, FDA submission, and eventual commercialization of the predictive diagnostic test.
“We are on the threshold of what could become the first truly predictive test to identify children at risk of developing severe scoliosis, opening the door to earlier interventions,” said Dr. Moreau. “I am excited about this strategic alliance with VB Spine. It reflects a bold and forward-looking vision and long-standing commitment to bringing transformative innovations to patients.”
VB Spine entered into a partnership to fund research of molecular genetics affecting pediatric scoliosis. The research will be conducted by Dr. Alain Moreau of the Centre de recherche Azrieli du CHU Sainte-Justine, Montreal, Canada.
In its agreement, VB Spine will receive exclusive worldwide license to commercialize and distribute any...
VB Spine entered into a partnership to fund research of molecular genetics affecting pediatric scoliosis. The research will be conducted by Dr. Alain Moreau of the Centre de recherche Azrieli du CHU Sainte-Justine, Montreal, Canada.
In its agreement, VB Spine will receive exclusive worldwide license to commercialize and distribute any predictive scoliosis tests derived from Dr. Moreau’s scoliosis research.
Dr. Moreau’s research began in 2001 with a focus on understanding the biological mechanisms behind idiopathic scoliosis and identifying whether biomarkers present in patient blood could help predict spinal deformity progression. Initial clinical studies launched in 2006 successfully demonstrated proof of concept, and subsequent peer-reviewed research has continued to validate the underlying science. The next phase of the project is expected to focus on further clinical validation, FDA submission, and eventual commercialization of the predictive diagnostic test.
“We are on the threshold of what could become the first truly predictive test to identify children at risk of developing severe scoliosis, opening the door to earlier interventions,” said Dr. Moreau. “I am excited about this strategic alliance with VB Spine. It reflects a bold and forward-looking vision and long-standing commitment to bringing transformative innovations to patients.”
Copy to clipboard 
